Three dates. Three stock price collapses. That is the pattern investors in Zoetis Inc. now face as a class action lawsuit moves toward its lead plaintiff deadline.
The law firm Glancy Prongay Wolke & Rotter LLP is gathering shareholders who bought Zoetis securities between January 14, 2025, and May 6, 2026. The window for filing a lead plaintiff motion approaches.
For those who lost money, the question is whether the company misled them about the true state of its business. Zoetis, the animal health giant, built its recent growth story on the Companion Animal portfolio — drugs and treatments for pets. That story has broken hard.
The numbers tell it plainly. On August 5, 2025, the company released second-quarter results.
Weakened demand trends in Companion Animal. Stock price fell. Investors took a hit.
Then November 4, 2025. Third-quarter results came out. Slowed growth across key Companion Animal franchises.
The company disclosed continued weakness in sales of Librela, its canine pain treatment. Competitive pressure mounted in dermatology and parasiticides.
Zoetis lowered its full-year sales outlook. The stock dropped again. May 7, 2026.
First-quarter 2026 results. Slowing overall revenue growth.
Declining Companion Animal sales performance. Worsening results. Another price decline.
Three quarters of bad news. Each time, the market reacted. Each time, investors who held on saw their holdings shrink further.
The central question in the lawsuit will be what Zoetis knew and when. Federal securities laws require companies to tell the truth about their business conditions.
If executives were aware of weakening demand, competitive threats, or problems with Librela before they disclosed them publicly, that could constitute fraud. The class action period — January 14, 2025 to May 6, 2026 — covers the time when the company was making statements about its performance that investors now allege were false or misleading. The Librela problem is particularly striking.
That drug was supposed to be a growth driver. Instead, it became a drag.
The company cited “continued weakness” in sales of the canine pain treatment. That is not a one-quarter blip. That is a trend.
Competitive pressure in dermatology and parasiticides tells a similar story. Zoetis faces rivals eating into its market share. The company’s response — lowering its full-year outlook — suggests management saw the problem getting worse, not better.
For investors, the math is brutal. A stock that falls on three separate earnings reports over nine months does not recover quickly.
Each drop compounds the losses. A shareholder who bought at the start of the class period and held through May 2026 watched their investment erode in stages. The lead plaintiff deadline will determine who drives the case.
Typically, the investor with the largest financial stake gets that role. They then represent the class.
The law firm is searching for that person now. What comes next depends on discovery. If documents show executives knew about the weakening demand before they told the market, the case gains force.
If the problems were genuinely unexpected, the company has a defense. The three consecutive quarters of bad news, however, make the “unexpected” argument harder to sell. Zoetis built its reputation on animal health.
Pets are not optional spending for most owners — but they are discretionary in a way that livestock medicine is not. When pet owners tighten budgets, companion animal sales suffer.
The company’s results suggest that is exactly what happened. The lawsuit will test whether Zoetis executives saw that coming and said nothing. Investors who lost money now have a narrow window to step forward.
After that, the case belongs to whoever does.
